Oregon Public Employees Retirement Fund raised its position in shares of ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report) by 7.4% during the 2nd quarter, Holdings Channel.com reports. The firm owned 4,354 shares of the specialty pharmaceutical company’s stock after acquiring an additional 300 shares during the period. Oregon Public Employees Retirement Fund’s holdings in ANI Pharmaceuticals were worth $234,000 as of its most recent SEC filing.
A number of other hedge funds also recently modified their holdings of ANIP. Ridgewood Investments LLC acquired a new position in ANI Pharmaceuticals during the first quarter valued at $53,000. Lazard Asset Management LLC acquired a new position in shares of ANI Pharmaceuticals in the 4th quarter valued at about $55,000. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of ANI Pharmaceuticals by 79.0% in the first quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 1,421 shares of the specialty pharmaceutical company’s stock worth $56,000 after purchasing an additional 627 shares in the last quarter. Quantbot Technologies LP acquired a new stake in shares of ANI Pharmaceuticals during the first quarter worth approximately $64,000. Finally, Systematic Financial Management LP purchased a new position in ANI Pharmaceuticals during the first quarter valued at approximately $68,000. Hedge funds and other institutional investors own 69.78% of the company’s stock.
ANI Pharmaceuticals Price Performance
Shares of NASDAQ:ANIP opened at $56.86 on Tuesday. The company has a debt-to-equity ratio of 0.70, a current ratio of 3.74 and a quick ratio of 2.89. The stock has a market capitalization of $1.15 billion, a P/E ratio of -118.46 and a beta of 1.06. The business has a 50-day moving average of $60.48 and a two-hundred day moving average of $52.20. ANI Pharmaceuticals, Inc. has a fifty-two week low of $32.16 and a fifty-two week high of $65.89.
Insider Buying and Selling
In related news, major shareholder Meridian Venture Partners Ii L sold 200,000 shares of ANI Pharmaceuticals stock in a transaction on Wednesday, August 16th. The shares were sold at an average price of $58.50, for a total value of $11,700,000.00. Following the transaction, the insider now owns 1,819,259 shares in the company, valued at approximately $106,426,651.50. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other ANI Pharmaceuticals news, major shareholder Meridian Venture Partners Ii L sold 200,000 shares of ANI Pharmaceuticals stock in a transaction that occurred on Wednesday, August 16th. The stock was sold at an average price of $58.50, for a total value of $11,700,000.00. Following the transaction, the insider now directly owns 1,819,259 shares of the company’s stock, valued at approximately $106,426,651.50. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Antonio R. Pera sold 3,000 shares of the stock in a transaction that occurred on Monday, August 14th. The shares were sold at an average price of $60.37, for a total value of $181,110.00. Following the completion of the sale, the director now directly owns 33,627 shares of the company’s stock, valued at $2,030,061.99. The disclosure for this sale can be found here. In the last three months, insiders sold 455,642 shares of company stock valued at $26,910,458. Company insiders own 28.50% of the company’s stock.
Wall Street Analysts Forecast Growth
A number of equities research analysts have issued reports on the stock. TheStreet upgraded shares of ANI Pharmaceuticals from a “c+” rating to a “b-” rating in a research report on Thursday, August 10th. StockNews.com started coverage on ANI Pharmaceuticals in a research report on Thursday, October 5th. They set a “hold” rating for the company. Guggenheim reaffirmed a “buy” rating and issued a $72.00 target price on shares of ANI Pharmaceuticals in a research report on Thursday, October 19th. HC Wainwright lifted their price target on ANI Pharmaceuticals from $60.00 to $73.00 and gave the company a “buy” rating in a report on Tuesday, August 22nd. Finally, Truist Financial restated a “buy” rating and issued a $70.00 price objective on shares of ANI Pharmaceuticals in a report on Monday, August 21st. One research analyst has rated the stock with a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, ANI Pharmaceuticals currently has a consensus rating of “Moderate Buy” and a consensus target price of $71.67.
Read Our Latest Report on ANIP
ANI Pharmaceuticals Company Profile
ANI Pharmaceuticals, Inc, a biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada. It focuses on producing controlled substances, oncology products, hormones and steroids, injectables, and other formulations, including extended release and combination products.
Further Reading
- Five stocks we like better than ANI Pharmaceuticals
- Stocks with Unusual Volume: How to Find Unusual Volume Stocks in Real Time
- Las Vegas Sands Stock May No Longer Be a Gamble
- What is the S&P/TSX Index?
- MarketBeat ‘Stock of the Week’: Is Gen Digital Undervalued?
- What is the Nikkei 225 index?
- The Value Deepens for Medtech Stocks: Reversal Imminent
Want to see what other hedge funds are holding ANIP? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ANI Pharmaceuticals, Inc. (NASDAQ:ANIP – Free Report).
Receive News & Ratings for ANI Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ANI Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
